EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Better Rejection‐Free Survival at Three Years in Kidney Transplant Recipients With Model‐Informed Precision Dosing of Mycophenolate Mofetil

Claire Villeneuve iD, Antoine Humeau, Caroline Monchaud, Marc Labriffe iD, Jean-Phillipe Rerolle, Lionel Couzi, Pierre-François Westeel, Isabelle Etienne, Nassim Kamar, Mathias Büchler, Antoine Thierry, Pierre Marquet iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3206 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Claire Villeneuve und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France. Hauptthemen laut MEDLINE: Mycophenolic Acid, Kidney Transplantation, Immunosuppressive Agents, Graft Rejection. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The clinical impact of individual dose adjustment of mycophenolate mofetil is still debated, due to conflicting results from randomized clinical trials. This retrospective study aimed to compare 3‐year rejection‐free survival and adverse effects between adult kidney transplant recipients (KTRs) with or without mycophenolate mofetil model‐informed precision dosing (MIPD). MIPD is defined here as mycophenolic acid area under the curve (AUC 0–12h ) estimation using a limited sampling strategy, pharmacokinetic models and Bayesian estimators; dose recommendation to reach AUC 0–12h = 45 mg.h/L; using a widely used online expert system. The study, nested in two multicenter prospective cohort studies, focused on patients who received a mycophenolate drug and were followed up for 1–3 years. Mycophenolate mofetil MIPD was prescribed as per local practice, on a regular basis, when deemed necessary, or not at all. The MIPD group included 341 KTRs and the control group 392. At 3 years, rejection‐free survival was respectively 91.2% and 80.6% ( P < 0.001) and the cumulative incidence of rejection 5.08% vs. 12.7% per patient × year (hazard ratio = 0.49 (0.34, 0.71), P < 0.001), corresponding to a 2.5‐fold reduction. Significant association with rejection‐free survival was confirmed in patients at low or high risk of rejection ( P = 0.017 and 0.013) and in patients on tacrolimus, but not on cyclosporine ( P < 0.001 and 0.205). The mycophenolate mofetil MIPD group had significantly more adverse effects, but most occurred before the first AUC 0–12h , suggesting some may be the reason why MIPD was ordered.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mycophenolic AcidKidney TransplantationImmunosuppressive AgentsGraft RejectionHumansMaleFemaleMiddle AgedRetrospective StudiesAdultBayes TheoremArea Under CurveProspective StudiesAgedModels, BiologicalGraft SurvivalTransplant Recipients

Substanzen

Mycophenolic AcidImmunosuppressive Agents

Autor:innen und Institutionen

  • Department of Pharmacology, Toxicology and Pharmacovigilance, Centre Hospitalier Universitaire de Limoges, Limoges, France.
  • Pharmacology & Transplantation, Institut National de la Santé et de la Recherche Médicale U1248, Université de Limoges, Limoges, France.
  • Fédération Hospitalo-Universitaire SUrvival oPtimization in ORgan Transplantation (FHU SUPORT), Limoges, France.
  • Department of Nephrology, Dialysis and Transplantation, Centre Hospitalier Universitaire de Limoges, Limoges, France.
  • Department of Nephrology, Transplantation, Dialysis, Centre Hospitalier Universitaire Pellegrin, Bordeaux, France.
  • Centre National de la Recherche Scientifique, UMR 5164 Immuno ConcEpT, Bordeaux University, Bordeaux, France.

ORCID-Profile: Claire Villeneuve, Marc Labriffe, Pierre Marquet

Zitieren

APA

Villeneuve, C., Humeau, A., Monchaud, C., Labriffe, M., Rerolle, J. P., Couzi, L., Westeel, P. F., Etienne, I., Kamar, N., Büchler, M., Thierry, A., & Marquet, P. (2024). Better Rejection‐Free Survival at Three Years in Kidney Transplant Recipients With Model‐Informed Precision Dosing of Mycophenolate Mofetil. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3206

Vancouver

Villeneuve C, Humeau A, Monchaud C, Labriffe M, Rerolle JP, Couzi L, et al. Better Rejection‐Free Survival at Three Years in Kidney Transplant Recipients With Model‐Informed Precision Dosing of Mycophenolate Mofetil. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3206

BibTeX
@article{Villeneuve2024,
  author = {Villeneuve, Claire and Humeau, Antoine and Monchaud, Caroline and Labriffe, Marc and Rerolle, Jean-Phillipe and Couzi, Lionel and Westeel, Pierre-François and Etienne, Isabelle and Kamar, Nassim and Büchler, Mathias and Thierry, Antoine and Marquet, Pierre},
  title = {Better Rejection‐Free Survival at Three Years in Kidney Transplant Recipients With Model‐Informed Precision Dosing of Mycophenolate Mofetil},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3206}
}
Kostenlos starten →